Dr. Thompson on Advancements in Treatments of Multiple Myeloma

Michael A. Thompson, MD, PhD
Published Online: Wednesday, Feb 15, 2017



Michael A. Thompson, MD, PhD, medical director, precision medicine, Vince Lombardi Cancer Clinic, Aurora Health Care, discusses advancements of treatments for patients with multiple myeloma.

In the field of multiple myeloma, many drugs received FDA approval in 2016. The next important steps are to discover effective ways to use those drugs, Thompson explains. One of the most promising drugs in the field of multiple myeloma is daratumumab (Darzalex). There is now more data looking at different populations of patients treated for longer lengths of time and it still appears beneficial.

Some researchers are looking at combinations of elotuzumab (Empliciti) with checkpoint inhibitors, Thompson says. Other noteworthy drugs in this field are ixazomib (Ninlaro), selinixor, and venetoclax (Venclexta).
 


Michael A. Thompson, MD, PhD, medical director, precision medicine, Vince Lombardi Cancer Clinic, Aurora Health Care, discusses advancements of treatments for patients with multiple myeloma.

In the field of multiple myeloma, many drugs received FDA approval in 2016. The next important steps are to discover effective ways to use those drugs, Thompson explains. One of the most promising drugs in the field of multiple myeloma is daratumumab (Darzalex). There is now more data looking at different populations of patients treated for longer lengths of time and it still appears beneficial.

Some researchers are looking at combinations of elotuzumab (Empliciti) with checkpoint inhibitors, Thompson says. Other noteworthy drugs in this field are ixazomib (Ninlaro), selinixor, and venetoclax (Venclexta).
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Expert Perspectives in PARP Inhibition: Evolving Management Strategies in Ovarian CancerJun 24, 20172.0
Oncology Consultations®: Identifying Best Practices of the Multidisciplinary Team in CINV ManagementJun 28, 20172.0
Publication Bottom Border
Border Publication
$emailPop$